|
R&D Systems
rh mdc ccl22 ![]() Rh Mdc Ccl22, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rh+mdc+ccl22/10__1158_slash_0008___5472__can___06___0261-53-6-8?v=R%26D+Systems Average 90 stars, based on 1 article reviews
rh mdc ccl22 - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
|
R&D Systems
recombinant human ![]() Recombinant Human, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rh+mdc+ccl22/pm16614259-31-0-6?v=R%26D+Systems Average 90 stars, based on 1 article reviews
recombinant human - by Bioz Stars,
2026-08
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cancer Research
Article Title: Specific Recruitment of CC Chemokine Receptor 4–Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
doi: 10.1158/0008-5472.can-06-0261
Figure Lengend Snippet: Figure 1. Chemotactic activity of the supernatants of HL cell lines. The chemotactic responses of human PBL induced by the supernatants of HL and ALCL cell lines, rh-TARC/CCL17 and rh-MDC/CCL22. The number of cells migrated (count/AL) into the lower well containing control medium is set as ‘‘one’’ and the relative numbers of cells of each subset migrated into the lower well containing the chemoattractants are presented. Horizontal dotted line, base unit. The supernatants of the HL cell lines did not show any chemotactic activity for whole lymphocytes (A) and CD8+
Article Snippet: Recombinant human (rh)-TARC/CCL17 (R&D Systems) and/or
Techniques: Activity Assay, Control
Journal: Cancer Research
Article Title: Specific Recruitment of CC Chemokine Receptor 4–Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
doi: 10.1158/0008-5472.can-06-0261
Figure Lengend Snippet: Figure 5. The attribution of the chemotactic activity of the supernatant of the HL cell line to TARC/CCL17 and MDC/CCL22 and KM2760-induced inhibition of the migration of CD4+CD25+ T cells. A to C, percentages were determined of CD4+ cells in PBMC, CD4+CCR4+ cells in PBMC, and CD4+CCR4+ cells in CD4+ cells, obtained from 15 healthy adult volunteers, incubated with KM2760 or Rituximab or without any antibody. Each closed circle represents the percentage of CD4+ cells in each PBMC, CD4+CCR4+ cells in each PBMC, and CD4+CCR4+ cells in each CD4+ cell population. Points, mean; bars, SD. *, P < 0.05, significant differences between each group (n.s., not significant). A 12-hour treatment with KM2760 significantly decreased the proportions of CD4+ cells in PBMC, CD4+CCR4+ cells in PBMC, and CD4+CCR4+ cells in CD4+ cells. D, the source of the chemotactic activity in the supernatants of the HL cell lines was examined by a chemotaxis assay of human PBL using the neutralizing antibodies antihuman TARC/CCL17 and antihuman MDC/CCL22 mAbs. Antihuman TARC/CCL17 alone or antihuman MDC/CCL22 mAb alone did not completely inhibit the migration of the CD4+CD25+ T cells induced by the supernatant of one of the HL cell lines, HDLM-2, which produces both TARC/CCL17 and MDC/CCL22. In contrast, the presence of both antibodies together caused an almost complete inhibition of the CD4+CD25+
Article Snippet: Recombinant human (rh)-TARC/CCL17 (R&D Systems) and/or
Techniques: Activity Assay, Inhibition, Migration, Incubation, Chemotaxis Assay